Né Romaric, Chevallier Olivier, Falvo Nicolas, Facy Olivier, Berthod Pierre-Emmanuel, Galland Christophe, Gehin Sophie, Midulla Marco, Loffroy Romaric
Department of Vascular and Interventional Radiology, François-Mitterrand Teaching Hospital, University of Burgundy, Dijon, France.
Department of Angiology and Vascular Medicine, François-Mitterrand Teaching Hospital, University of Burgundy, Dijon, France.
Quant Imaging Med Surg. 2018 Apr;8(3):280-290. doi: 10.21037/qims.2018.04.03.
Onyx is a liquid embolic agent, which is approved for the treatment of cerebral vascular lesions but still rarely used in peripheral interventional radiology. The goal of this study is to report the feasibility and safety of embolization with Onyx for peripheral hemostatic and non-hemostatic endovascular procedures.
Retrospective study of all consecutive patients who underwent visceral or peripheral embolization with Onyx for hemostatic or non-hemostatic purpose in our department between May 2014 and November 2016. Demographic data, clinical presentation, underlying etiology, culprit vessel, endovascular procedure, pain during embolization, outcomes, and follow-up data were collected.
Fifty patients (males, 34; females, 16; mean age, 56±18 years; range, 15-89 years) were included. Twenty-nine (58%) of patients underwent hemostatic embolization for arterial (n=22, 44%) or venous (n=7, 14%) bleeding lesions, whereas 21 (42%) of patients underwent non-hemostatic embolization for arterial aneurysms (n=8, 16%), preoperative portal vein deprivation (n=6, 12%) or other indications (n=7, 14%). Onyx-18 was used in 37 (74%) patients, Onyx-34 in 9 (18%) patients, and a combination of both in 4 (8%) patients. Onyx was used alone in 25 (50%) patients and in combination with other agent in 25 (50%) patients. Mean number of Onyx vials used was 3.7 (range, 1-17). Immediate technical success rate was 100%. Primary clinical success was achieved in all patients. Recurrent bleeding occurred in two patients. Significant pain (pain score ≥3) was noted during injection in 10 (20%) patients. No major complication or side effects were noted within 1 month.
Transcatheter embolization with Onyx is feasible and safe in the peripheral arterial or venous vasculature for both bleeding and non-bleeding patients whatever the anatomic site.
Onyx是一种液体栓塞剂,已被批准用于治疗脑血管病变,但在外周介入放射学中仍很少使用。本研究的目的是报告使用Onyx进行外周止血和非止血性血管内介入栓塞术的可行性和安全性。
回顾性研究2014年5月至2016年11月期间在我科接受Onyx内脏或外周栓塞术以达到止血或非止血目的的所有连续患者。收集人口统计学数据、临床表现、潜在病因、责任血管、血管内介入操作、栓塞过程中的疼痛、结果及随访数据。
纳入50例患者(男性34例,女性16例;平均年龄56±18岁;范围15 - 89岁)。29例(58%)患者因动脉(n = 22,44%)或静脉(n = 7,14%)出血性病变接受止血栓塞术,而21例(42%)患者因动脉瘤(n = 8,16%)、术前门静脉阻断(n = 6,12%)或其他指征(n = 7,14%)接受非止血栓塞术。37例(74%)患者使用Onyx - 18,9例(18%)患者使用Onyx - 34,4例(8%)患者联合使用两者。25例(50%)患者单独使用Onyx,25例(50%)患者与其他药物联合使用。Onyx平均使用瓶数为3.7瓶(范围1 - 17瓶)。即刻技术成功率为100%。所有患者均取得了初步临床成功。2例患者出现复发出血。10例(20%)患者在注射过程中出现明显疼痛(疼痛评分≥3)。1个月内未发现重大并发症或副作用。
无论解剖部位如何,对于出血和非出血患者,经导管使用Onyx在外周动脉或静脉血管系统中进行栓塞是可行且安全的。